Coronary Artery Disease Outcome Trials

COMPASS (BAY 59-7939/15786 Trial) (ENROLLMENT CLOSED)

A Randomized Controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS-Cardiovascular Outcomes for People using Anticoagulation Strategies).Principle Investigator:Ronald Fields, M.D., F.A.C.C.Sponsor: Bayer HealthCare Pharmaceuticals, Inc.